Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.

Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, Neel BG.

Dev Cell. 2010 May 18;18(5):750-62. doi: 10.1016/j.devcel.2010.03.009.

2.

Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.

Jopling C, van Geemen D, den Hertog J.

PLoS Genet. 2007 Dec;3(12):e225.

3.

Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.

Bonetti M, Paardekooper Overman J, Tessadori F, Noël E, Bakkers J, den Hertog J.

Development. 2014 May;141(9):1961-70. doi: 10.1242/dev.106310. Epub 2014 Apr 9.

4.

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).

Qiu W, Wang X, Romanov V, Hutchinson A, Lin A, Ruzanov M, Battaile KP, Pai EF, Neel BG, Chirgadze NY.

BMC Struct Biol. 2014 Mar 14;14:10. doi: 10.1186/1472-6807-14-10.

5.

Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Yu ZH, Xu J, Walls CD, Chen L, Zhang S, Zhang R, Wu L, Wang L, Liu S, Zhang ZY.

J Biol Chem. 2013 Apr 12;288(15):10472-82. doi: 10.1074/jbc.M113.450023. Epub 2013 Mar 1.

6.

PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.

Paardekooper Overman J, Yi JS, Bonetti M, Soulsby M, Preisinger C, Stokes MP, Hui L, Silva JC, Overvoorde J, Giansanti P, Heck AJ, Kontaridis MI, den Hertog J, Bennett AM.

Mol Cell Biol. 2014 Aug;34(15):2874-89. doi: 10.1128/MCB.00135-14. Epub 2014 May 27.

7.

Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.

Müller PJ, Rigbolt KT, Paterok D, Piehler J, Vanselow J, Lasonder E, Andersen JS, Schaper F, Sobota RM.

J Proteomics. 2013 Jun 12;84:132-47. doi: 10.1016/j.jprot.2013.04.005. Epub 2013 Apr 11.

PMID:
23584145
8.

PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?

Lauriol J, Kontaridis MI.

Trends Cardiovasc Med. 2011 May;21(4):97-104. doi: 10.1016/j.tcm.2012.03.006. Review.

9.

Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.

Noda S, Takahashi A, Hayashi T, Tanuma S, Hatakeyama M.

Biochem Biophys Res Commun. 2016 Jan 22;469(4):1133-9. doi: 10.1016/j.bbrc.2015.12.117. Epub 2015 Dec 29.

PMID:
26742426
10.

Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.

Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX, Tzeng CM.

Curr Cancer Drug Targets. 2014;14(6):567-88. Review.

PMID:
25039348
11.

Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.

Miura K, Wakayama Y, Tanino M, Orba Y, Sawa H, Hatakeyama M, Tanaka S, Sabe H, Mochizuki N.

Oncogene. 2013 Nov 7;32(45):5292-301. doi: 10.1038/onc.2012.571. Epub 2013 Jan 14.

PMID:
23318428
12.

PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.

Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG.

J Biol Chem. 2006 Mar 10;281(10):6785-92. Epub 2005 Dec 23.

13.

Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.

Yu ZH, Zhang RY, Walls CD, Chen L, Zhang S, Wu L, Liu S, Zhang ZY.

Biochemistry. 2014 Jul 1;53(25):4136-51. doi: 10.1021/bi5002695. Epub 2014 Jun 17.

14.
15.

LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.

Ishida H, Kogaki S, Narita J, Ichimori H, Nawa N, Okada Y, Takahashi K, Ozono K.

Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1531-9. doi: 10.1152/ajpheart.00216.2011. Epub 2011 Jul 29.

16.

New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.

Schramm C, Edwards MA, Krenz M.

J Biol Chem. 2013 Jun 21;288(25):18335-44. doi: 10.1074/jbc.M113.483800. Epub 2013 May 14.

17.

Phosphoproteomics-mediated identification of Fer kinase as a target of mutant Shp2 in Noonan and LEOPARD syndrome.

Paardekooper Overman J, Preisinger C, Prummel K, Bonetti M, Giansanti P, Heck A, den Hertog J.

PLoS One. 2014 Sep 3;9(9):e106682. doi: 10.1371/journal.pone.0106682. eCollection 2014.

18.

The tyrosine phosphatase Shp2 (PTPN11) in cancer.

Chan G, Kalaitzidis D, Neel BG.

Cancer Metastasis Rev. 2008 Jun;27(2):179-92. doi: 10.1007/s10555-008-9126-y. Review.

PMID:
18286234
19.

Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.

Martinelli S, Torreri P, Tinti M, Stella L, Bocchinfuso G, Flex E, Grottesi A, Ceccarini M, Palleschi A, Cesareni G, Castagnoli L, Petrucci TC, Gelb BD, Tartaglia M.

Hum Mol Genet. 2008 Jul 1;17(13):2018-29. doi: 10.1093/hmg/ddn099. Epub 2008 Mar 27.

20.

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.

Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, Mackerell AD Jr, Tang LD, Qu CK.

Mol Cancer Ther. 2013 Sep;12(9):1738-48. doi: 10.1158/1535-7163.MCT-13-0049-T. Epub 2013 Jul 3.

Items per page

Supplemental Content

Write to the Help Desk